title: [Endovesical treatment as an alternative to BCG for intermediate or high-risk NMI bladder cancer].
abstract: A shortage of BCG is foreseen till the end of 2013. Which will be the management of intermediate and high-risk NMI-BC if BCG will not be available? In patients harboring high-risk NMI tumors, particularly T1G3 and Tis, the first therapeutic choice is radical cystectomy. Device-assisted therapies, although showing promising results, should be considered only for selected patients. In intermediate risk patients, intravesical chemotherapy remains a legitimate option even if BCG is available. Thus, in a period of BCG shortage, intravesical chemotherapy should be offered, preferably preceded by early instillation, according to the EAU guidelines.
authors.affiliation: Sezione di Urologia, Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo - Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Serretta
authors.forename: Renzo
authors.initials: R
authors.lastname: Colombo
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage; D006801:Humans; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018570:Risk Assessment; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine